Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-cohort, Open-label, Single arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's disease (Including Systemic Juvenile Idiopathic Arthritis and Adult onset Still's disease) or with MAS in Systemic Lupus Erythematous

Next Previous
Trial Profile

A Two-cohort, Open-label, Single arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's disease (Including Systemic Juvenile Idiopathic Arthritis and Adult onset Still's disease) or with MAS in Systemic Lupus Erythematous

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emapalumab (Primary)
  • Indications Adult-onset Still's disease; Juvenile rheumatoid arthritis; Macrophage activation syndrome; Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms EMERALD; NI0501-14
  • Sponsors Swedish Orphan Biovitrum

Most Recent Events

  • 11 Jun 2025 Status changed from active, no longer recruiting to completed.
  • 28 May 2025 According to Swedish Orphan Biovitrum media release, company will present data from this trial at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025.
  • 27 Feb 2025 According to Sobi media release, company announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still's disease. The application was granted Priority Review with a PDUFA date of June 27

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top